LOGIN  |  REGISTER
Assertio

CooperCompanies to Present at the Wells Fargo Healthcare Conference

August 02, 2023 | Last Trade: US$95.68 0.50 0.53

SAN RAMON, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO), will participate in the Wells Fargo Healthcare Conference on Wednesday, September 6, 2023. Al White, President and CEO, will represent the Company in a session scheduled to begin at 3:00 PM ET.

The webcast will be available to investors and other interested parties by accessing the CooperCompanies’ website at http://investor.coopercos.com. A replay of the event will be available on the same webpage following its conclusion.

About CooperCompanies

CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.

Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page